These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 26804029

  • 1. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.
    Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
    Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.
    J Neurosci; 2014 Sep 24; 34(39):12953-62. PubMed ID: 25253844
    [Abstract] [Full Text] [Related]

  • 3. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M, Viaro R, Trapella C, Marti M, Morari M.
    Exp Neurol; 2011 Mar 24; 228(1):126-37. PubMed ID: 21215744
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
    Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G.
    J Pharmacol Exp Ther; 2007 Jun 24; 321(3):968-74. PubMed ID: 17329551
    [Abstract] [Full Text] [Related]

  • 5. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS, Marti M, Morari M.
    Neuroscience; 2010 Mar 10; 166(1):40-8. PubMed ID: 20006677
    [Abstract] [Full Text] [Related]

  • 6. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.
    Gouty S, Brown JM, Rosenberger J, Cox BM.
    Neuroscience; 2010 Aug 11; 169(1):269-78. PubMed ID: 20417255
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
    Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G.
    J Pharmacol Exp Ther; 2007 Jun 11; 321(3):961-7. PubMed ID: 17329552
    [Abstract] [Full Text] [Related]

  • 9. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
    Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M.
    J Neurosci; 2004 Jul 28; 24(30):6659-66. PubMed ID: 15282268
    [Abstract] [Full Text] [Related]

  • 10. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
    Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.
    Br J Pharmacol; 2013 Feb 28; 168(4):863-79. PubMed ID: 22994368
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
    Liao YY, Jiang F, Chiou LC.
    Eur J Pharmacol; 2011 Apr 25; 657(1-3):84-8. PubMed ID: 21300055
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.
    Di Benedetto M, Cavina C, D'Addario C, Leoni G, Candeletti S, Cox BM, Romualdi P.
    Neuropharmacology; 2009 Mar 25; 56(4):761-7. PubMed ID: 19162046
    [Abstract] [Full Text] [Related]

  • 19. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS, Lazzarini M, Martin S, Amar M, Stühmer W, Kirchhoff F, Gomes LA, Lanfumey L, Prediger RD, Sepulveda JE, Del-Bel EA, Raisman-Vozari R.
    Neurotox Res; 2016 Apr 25; 29(3):364-80. PubMed ID: 26403659
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
    Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L.
    J Pharmacol Exp Ther; 2011 Nov 25; 339(2):687-93. PubMed ID: 21859931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.